trigeminal neuralgia; impact on quality of life (9/10); this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority-web. the reporter is the patient. regulatory number: it-minisal02-842881. a 47 year-old female patient received bnt162b2 (comirnaty), intramuscular, administered in arm left, administration date 15jul2021 10:12 (lot number: ff0688) as dose 2, 0.3 ml,single for covid-19 immunisation. relevant medical history included: "benign meningioma" (unspecified if ongoing). the patient's concomitant medications were not reported. vaccination history included: comirnaty (dose 1), administration date: 10jun2021, for covid-19 immunisation. the following information was reported: trigeminal neuralgia (disability) with onset 20jul2021, outcome "not recovered", described as "trigeminal neuralgia"; quality of life decreased (disability) with onset 20jul2021, outcome "not recovered", described as "impact on quality of life (9/10)". therapeutic measures were taken as a result of trigeminal neuralgia, quality of life decreased. reporter comment: benign meningioma. clinical course: onset of trigeminal neuralgia after second covid vaccination with pfizer on 15jul2021. neuralgia is still present and treated with antiepileptics with side effects. very intense pain, very high influence on the quality of life, the patient considers the reaction serious and it is decided to keep it as such, even if an event not present in the ime list. - actions taken (i am being treated with antiepileptics with great side effects. the pain is unbearable every day with elimination of social life and inability to carry out any activity) - impact on quality of life (9/10). no follow-up attempts are possible. no further information is expected.; reporter's comments: benign meningioma